Research programme: anticancer angiogenesis inhibitors - Bionomics

Drug Profile

Research programme: anticancer angiogenesis inhibitors - Bionomics

Alternative Names: BNO69 siRNA therapeutics - Bionomics; BNO69-targeting therapeutics - Bionomics

Latest Information Update: 24 Aug 2010

Price : $50

At a glance

  • Originator Bionomics
  • Class Small interfering RNA; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 24 Aug 2010 Preclinical development is ongoing in Australia
  • 03 Aug 2004 Preclinical trials in Solid tumours in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top